Forty Seven, Inc. to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association (EHA)
MENLO PARK, Calif., May 17, 2018 /PRNewswire/ -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that preliminary data from its ongoing Phase 1 clinical trial evaluating 5F9 as a monotherapy for the treatment of relapsed/refractory acute myeloid leukemia will be presented in a poster presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden, June 14-17, 2018.
The accepted abstract is listed below and is now available online on the EHA website: http://ehaweb.org/congress/23rd-c/lkey-information/.
Initial phase 1 results of the first-in-class anti-CD47 antibody Hu5F9-G4 in relapsed/refractory acute myeloid leukemia patients
Presentation Date & Time: Friday, June 15, 2018 from 5:30 p.m. – 7:00 p.m. CEST (11:30 a.m. – 1:00 p.m. ET)
Session Title: Acute myeloid leukemia - Clinical
Abstract Number: PF232
Location: Poster Area, Stockholmsmässan
About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in five clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
SOURCE Forty Seven, Inc.